EFFECTIVE FIRST-LINE SSRI THERAPY FOR OCD...

EMERGING FROM THE PROFOUND ANXIETY OF OCD

LOW INCIDENCE OF AGITATION
- 2% vs 1% for placebo

LOW INCIDENCE OF SEXUAL DYSFUNCTION
- LUVOX® Tablets vs placebo*: decreased libido 2% vs 1%; delayed ejaculation 8% vs 1%; anorgasmia 2% vs 0%; impotence 2% vs 1%

FAVORABLE TOLERABILITY PROFILE
- Relatively low incidence of anticholinergic side effects in controlled trials of OCD and depression. LUVOX® Tablets vs placebo: dizziness 11% vs 6%; constipation 10% vs 8%; dry mouth 14% vs 10%
- For adults, the most commonly observed adverse events compared to placebo were somnolence 22% vs 8%; insomnia 21% vs 10%; nervousness 12% vs 5%; nausea 40% vs 14%; asthenia 14% vs 6%
- Adverse events in children and adolescents were similar to those observed in adult studies. The most commonly observed adverse events compared to placebo were: agitation 12% vs; hyperkinesia 12% vs 3%; depression 5% vs 0%; dysmenorrhea 7% vs 3%; flatulence 5% vs 0%; rash 7% vs 3%
- Concomitant use of LUVOX® Tablets and monoamine oxidase inhibitors is not recommended

*Parameters occurring ≥ 1% with fluvoxamine maleate.
Please see brief summary of prescribing information on adjacent page.

LUVOX®
fluvoxamine maleate
25 mg TABLETS  50 mg & 100 mg SCORED TABLETS

First-line SSRI therapy for obsessions and compulsions

The first SSRI indicated for OCD in children and adolescents

AVAILABLE IN 25-mg TABLETS

https://doi.org/10.1017/S1092852900031072 Published online by Cambridge University Press